Literature DB >> 26989650

Spontaneous rectus sheath hematoma in a patient treated with apixaban.

Halil Aktas1, Sinan Inci1, Pinar Dogan1, Ibrahim Izgu1.   

Abstract

Apixaban, a non-vitamin K antagonist oral anticoagulants, is a Factor Xa inhibitor that is prescribed for the treatment of non valvular atrial fibrillation. Rectus sheath hematoma is a rare but significant complication of oral anticoagulant treatment. The important causes of rectus sheath hematoma include treatment with anticoagulants, hematologic diseases, trauma, intense physical activity, coughing, sneezing and pregnancy. In this report, we describe case of a 71-year-old woman undergoing apixaban treatment for non valvular atrial fibrillation who presented with spontaneous rectus sheath hematoma.

Entities:  

Keywords:  Apixaban; oral anticoagulant; rectus sheath hematoma

Year:  2016        PMID： 26989650      PMCID： PMC4761585          DOI： 10.5582/irdr.2015.01039

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN： 2186-3644


  11 in total

1.  Retracted: Spontaneous rectus sheath haematoma associated with rivaroxaban treatment.

Authors:  A Tas Tuna; O Palabiyik; S G Beyaz
Journal:  J Clin Pharm Ther       Date:  2014-11-10       Impact factor: 2.512

2.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Europace       Date:  2013-05       Impact factor: 5.214

3.  Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.

Authors:  Ranjan Pathak; Anil Pandit; Paras Karmacharya; Madan Raj Aryal; Sushil Ghimire; Dilli Ram Poudel; Fadi E Shamoun
Journal:  Am J Cardiol       Date:  2014-11-13       Impact factor: 2.778

Review 4.  Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?

Authors:  Thaddaus Hellwig; Michael Gulseth
Journal:  Ann Pharmacother       Date:  2013-10-09       Impact factor: 3.154

5.  Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

Authors:  Charles E Frost; Wonkyung Byon; Yan Song; Jessie Wang; Alan E Schuster; Rebecca A Boyd; Donglu Zhang; Zhigang Yu; Clapton Dias; Andrew Shenker; Frank LaCreta
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

6.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

7.  Rectus sheath hematoma: review of 126 cases at a single institution.

Authors:  W Brett Cherry; Paul S Mueller
Journal:  Medicine (Baltimore)       Date:  2006-03       Impact factor: 1.889

8.  Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.

Authors:  Elaine M Hylek; Claes Held; John H Alexander; Renato D Lopes; Raffaele De Caterina; Daniel M Wojdyla; Kurt Huber; Petr Jansky; Philippe Gabriel Steg; Michael Hanna; Laine Thomas; Lars Wallentin; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2014-03-19       Impact factor: 24.094

9.  Apixaban metabolism and pharmacokinetics after oral administration to humans.

Authors:  Nirmala Raghavan; Charles E Frost; Zhigang Yu; Kan He; Haiying Zhang; W Griffith Humphreys; Donald Pinto; Shiangyuan Chen; Samuel Bonacorsi; Pancras C Wong; Donglu Zhang
Journal:  Drug Metab Dispos       Date:  2008-10-02       Impact factor: 3.922

10.  Spontaneous rectus sheath hematoma during rivaroxaban therapy.

Authors:  Ibrahim Kocayigit; Yusuf Can; Salih Sahinkus; Ercan Aydın; Mehmet Bulent Vatan; Harun Kılıc; Huseyin Gunduz
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200
View more
  4 in total

1.  Rectus Sheath Hematoma Associated with Apixaban.

Authors:  Kulothungan Gunasekaran; Amanda R McFee Winans; Swetha Murthi; Mudassar Raees Ahmad; Scott Kaatz
Journal:  Clin Pract       Date:  2017-08-01

Review 2.  A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants.

Authors:  Kulothungan Gunasekaran; Venkat Rajasurya; Joe Devasahayam; Mandeep Singh Rahi; Arul Chandran; Kalaimani Elango; Goutham Talari
Journal:  J Clin Med       Date:  2020-09-15       Impact factor: 4.241

3.  Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.

Authors:  Silvia Fernandez; Camille Lenoir; Caroline Samer; Victoria Rollason
Journal:  Pharmacol Res Perspect       Date:  2020-10

4.  Spontaneous rectus sheath hematoma associated with apixaban in an elderly gentleman with chronic obstructive airway disease - a case report.

Authors:  Cheuk-Lik Wong; Clarence Hao-Yu So
Journal:  Thromb J       Date:  2022-10-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.